Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.24 (
mitogen-activated protein kinase
)
95,810
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We previously reported that SUMOylation promotes the aggregation of ataxin-1 and
JNK
is involved in the process. Here we show that
dual-specificity phosphatase 18
(
DUSP18
), a member of protein tyrosine phosphatases, exerts the opposite effects on ataxin-1.
DUSP18
associated with ataxin-1 and suppressed
JNK
activated by ataxin-1. Interestingly
DUSP18
, but not the other DUSPs interacting with ataxin-1, caused the mobility shift of ataxin-1. De-phosphorylation by
DUSP18
was initially suspected as a cause for such an effect; however, the phosphorylation of ataxin-1 was unchanged. Instead
DUSP18
inhibited SUMOylation and reduced ataxin-1 aggregation. The catalytic mutant of
DUSP18
failed to reduce the SUMOylation and aggregation of ataxin-1 indicating that the phosphatase activity is indispensable for the effects. Moreover,
DUSP18
disrupted the co-localization of ataxin-1 with the PML component Sp100. These results together implicate that
JNK
and
DUSP18
reciprocally modulate the SUMOylation, which plays a regulatory role in the aggregation of ataxin-1.
...
PMID:Dual-specificity phosphatase 18 modulates the SUMOylation and aggregation of Ataxin-1. 2985 74